Iovance Biotherapeutics, Inc. (IOVA) Reaches $15.20 After 6.00% Up Move; Riverpoint Capital Management Trimmed Its Electronic Arts (EA) Holding

June 5, 2018 - By Marguerite Chambers

Electronic Arts Inc. (NASDAQ:EA) Logo

Riverpoint Capital Management Llc decreased Electronic Arts Inc (EA) stake by 6.53% reported in 2018Q1 SEC filing. Riverpoint Capital Management Llc sold 7,563 shares as Electronic Arts Inc (EA)’s stock rose 2.55%. The Riverpoint Capital Management Llc holds 108,282 shares with $13.13M value, down from 115,845 last quarter. Electronic Arts Inc now has $41.82B valuation. The stock increased 1.23% or $1.65 during the last trading session, reaching $136.31. About 1.28 million shares traded. Electronic Arts Inc. (NASDAQ:EA) has risen 15.83% since June 5, 2017 and is uptrending. It has outperformed by 3.26% the S&P500. Some Historical EA News: ; 15/05/2018 – EMINENCE BOOSTED LEN, PZZA, EA, MGM, LQ IN 1Q: 13F; 12/04/2018 – ELECTRONIC ARTS INC SAYS LAURA MIELE WILL BECOME CO’S CHIEF STUDIOS OFFICER; 08/05/2018 – ELECTRONIC ARTS INC EA.O – FY 2019 NET BOOKINGS IS EXPECTED TO BE APPROXIMATELY $5.55 BILLION; 23/05/2018 – Electronic Arts: ‘Battlefield V’ to Launch Oct. 19; 08/05/2018 – Electronic Arts Sees FY19 Rev $5.6B; 08/05/2018 – Electronic Arts Sees FY19 EPS $3.55; 07/03/2018 EA and Maxis Invite Players to Play with Life in The Sims Mobile, Available Worldwide Today; 23/05/2018 – ELECTRONIC ARTS MAY BE RAISED BY MOODY’S; 20/03/2018 – S&PGR Upgrades Electronic Arts Inc. To ‘BBB+’; Outlook Stable; 22/05/2018 – Electronic Arts Acquires Cloud Gaming Technology & Talent

The stock of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a huge mover today! The stock increased 2.70% or $0.4 during the last trading session, reaching $15.2. About 2.48 million shares traded or 226.21% up from the average. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has risen 159.35% since June 5, 2017 and is uptrending. It has outperformed by 146.78% the S&P500. Some Historical IOVA News: ; 06/04/2018 – IOVANCE SAYS STOCKHOLDER DERIVATIVE COMPLAINT FILED MARCH 28; 08/03/2018 Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Cor; 15/05/2018 – Ghost Tree Capital Buys 1.1% of Iovance Biotherapeutics; 01/05/2018 – Iovance Biotherapeutics, Inc. | autologous tumor infiltrating lymphocytes (TIL) | N/A | 04/30/2018 | Treatment of cervical cancer with a tumor size greater than 2 cm; 12/03/2018 – Iovance Biotherapeutics 4Q Adj Loss/Shr 32c; 19/04/2018 – DJ Iovance Biotherapeutics Inc, Inst Holders, 1Q 2018 (IOVA); 12/03/2018 – IOVANCE – ANTICIPATES CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE BETWEEN $190 MLN AND $210 MLN AT DECEMBER 31; 11/05/2018 – RXI PHARMACEUTICALS – SYNERGIES BETWEEN CO’S SELF-DELIVERING RNAI THERAPEUTIC PLATFORM & IOVANCE TIL CELL THERAPY APPROACH TO BE EXPLORED PRECLINICALLY; 08/03/2018 – lovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018; 11/05/2018 – RXi Pharmaceuticals Enters Into Material Transfer Agreement With Iovance BiotherapeuticsThe move comes after 9 months positive chart setup for the $1.36B company. It was reported on Jun, 5 by We have $16.11 PT which if reached, will make NASDAQ:IOVA worth $81.78M more.

More notable recent Electronic Arts Inc. (NASDAQ:EA) news were published by: which released: “EA sets Oct. 19 for ‘Battlefield V’ release” on May 23, 2018, also with their article: “Live Services Are Like Taxes For Gamers” published on May 07, 2018, published: “Here’s Why Electronic Arts Doesn’t Want to Pay a Dividend” on May 31, 2018. More interesting news about Electronic Arts Inc. (NASDAQ:EA) were released by: and their article: “Electronic Arts Rides the Esports Wave” published on May 11, 2018 as well as‘s news article titled: “Wedbush’s Red-Hot Best Idea List Going Into Summer” with publication date: June 02, 2018.

Analysts await Electronic Arts Inc. (NASDAQ:EA) to report earnings on July, 26. They expect $-0.11 earnings per share, down 130.56% or $0.47 from last year’s $0.36 per share. After $1.13 actual earnings per share reported by Electronic Arts Inc. for the previous quarter, Wall Street now forecasts -109.73% negative EPS growth.

Since December 14, 2017, it had 0 buys, and 47 insider sales for $33.68 million activity. 5,000 Electronic Arts Inc. (NASDAQ:EA) shares with value of $614,841 were sold by Soderlund Patrick. Shares for $1.36M were sold by Wilson Andrew on Wednesday, May 23. Bruzzo Chris sold $162,767 worth of stock or 1,500 shares. 750 shares were sold by Miele Laura, worth $95,987. Another trade for 1,000 shares valued at $125,770 was made by Schatz Jacob J. on Tuesday, March 20. Singh Vijayanthimala sold $24,908 worth of stock or 200 shares. Warren Denise had sold 1,000 shares worth $132,710.

Riverpoint Capital Management Llc increased Enterprise Prods Partners L (NYSE:EPD) stake by 15,568 shares to 259,999 valued at $6.37 million in 2018Q1. It also upped Celgene Corp (NASDAQ:CELG) stake by 5,851 shares and now owns 118,717 shares. Fastenal Co (NASDAQ:FAST) was raised too.

Among 30 analysts covering Electronic Arts (NASDAQ:EA), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Electronic Arts had 98 analyst reports since July 28, 2015 according to SRatingsIntel. As per Wednesday, February 1, the company rating was maintained by Mizuho. The firm has “Buy” rating by Stifel Nicolaus given on Monday, October 26. The rating was maintained by Stifel Nicolaus on Friday, October 6 with “Buy”. The rating was maintained by SunTrust on Friday, January 12 with “Buy”. The stock of Electronic Arts Inc. (NASDAQ:EA) has “Buy” rating given on Wednesday, January 31 by Bernstein. Bank of America upgraded the stock to “Buy” rating in Wednesday, July 26 report. The stock of Electronic Arts Inc. (NASDAQ:EA) earned “Buy” rating by Piper Jaffray on Friday, July 28. The company was maintained on Thursday, November 2 by BMO Capital Markets. Morgan Stanley downgraded the shares of EA in report on Friday, January 12 to “Hold” rating. The firm earned “Buy” rating on Tuesday, February 9 by Hilliard Lyons.

Investors sentiment is 0.85 in Q1 2018. Its the same as in 2017Q4. It has no change, as 72 investors sold EA shares while 230 reduced holdings. only 84 funds opened positions while 173 raised stakes. 273.19 million shares or 2.68% less from 280.71 million shares in 2017Q4 were reported. Whittier Co holds 386 shares. Ny State Common Retirement Fund, New York-based fund reported 822,966 shares. Zeke Capital Limited Company holds 0.07% in Electronic Arts Inc. (NASDAQ:EA) or 6,654 shares. Trexquant Invest Lp owns 19,272 shares for 0.16% of their portfolio. Baystate Wealth Mgmt Llc invested 0% in Electronic Arts Inc. (NASDAQ:EA). Ing Groep Nv invested 0.01% in Electronic Arts Inc. (NASDAQ:EA). Kames Cap Pcl holds 0.09% of its portfolio in Electronic Arts Inc. (NASDAQ:EA) for 27,555 shares. State Of Tennessee Treasury Department accumulated 0.06% or 101,629 shares. Patten Patten Inc Tn reported 19,765 shares. Intact Inv Mngmt Incorporated accumulated 0.02% or 5,000 shares. Texas Yale Capital accumulated 1,777 shares. British Columbia Invest Mngmt invested in 0.26% or 279,478 shares. Employees Retirement Sys Of Ohio reported 211,903 shares. Vanguard Group Inc invested in 0.12% or 22.20M shares. Brant Point Investment Lc invested 0.41% in Electronic Arts Inc. (NASDAQ:EA).

Analysts await Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to report earnings on August, 7. They expect $-0.32 EPS, up 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.31 actual EPS reported by Iovance Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.23% negative EPS growth.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.36 billion. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More recent Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news were published by: which released: “Iovance Biotherapeutics to Present at Two Investor Conferences in June” on May 31, 2018. Also published the news titled: “Vitality Biopharma to Present at the 8th Annual LD Micro Invitational” on May 30, 2018.‘s news article titled: “Report: Exploring Fundamental Drivers Behind ServisFirst Bancshares, Iovance Biotherapeutics, Inc., MarineMax …” with publication date: May 29, 2018 was also an interesting one.

Electronic Arts Inc. (NASDAQ:EA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts